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Objective: CFRD is the most common comorbidity in CF. The recommended
treatment of CFRD is Insulin, but other options are also in use. Only few data
exist related to other treatment options. Therefore we analyzed the German CF-
register for the documented therapy of CFRD.
Methods: Data from the German CF-register were used from patients with CFRD
in 2010 in a retrospective observational study. Delta FEV1% and delta BMI-Z-
score from 2 year before diagnosis of CFRD to year of diagnosis and from year of
diagnosis to 2 years after were calculated for each treatment group (Insulin, oral
anti-diabetic drugs, no therapy with drugs) and compared using ANOVA-analysis.
Results: 798 patients with CFRD were documented in 2010. 51.9%.were female;
age (mean±SD) at diagnosis 23.8±9.3 years; CFRD duration 5.8±4.5 years.
Treatment: 57.6% Insulin, 9.8% oral anti-diabetic drugs, 2.1% with both and 30.2%
without any drug treatment. The mean (±SD) CFRD duration in the non-treated
patients was 4.5±4.0 years. ANOVA tests showed no differences between treatment
groups regarding changes in FEV1% and BMI-Z-score from 2 years before to the
year of diagnosis and delta FEV1 and delta BMI-Z-score and from year of diagnosis
to 2 years later.
Conclusions: The percentage of patients treated with oral anti-diabetic drugs is in
the international published range. We know the weakness of retrospective studies.
Nevertheless the numbers are high and the observation time is long. Our data point
to the question if insulin is the only successful initial treatment of CFRD in all
CF patients. At least a part of patients with CFRD seems to be well treated with
other regimes.
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Objective: The aim of DIAMUCO study is to describe the natural history of the
glucose tolerance (GT) and to identify predictive factors of the changes in GT in cystic
ﬁbrosis (CF) patients for a four-year period. We present the patients’ characteristics at
inclusion.
Patients and Methods: We used a cross-sectional study design and included a total of
228 patients, 111 children (between 10 and 18 years) and 117 adults between 2009 and
2011. All patients had an annual screening. Patients were classiﬁed as having normal
glucose tolerance (NGT), impaired glucose tolerance (IGT), or CF-related diabetes
mellitus (CFRD) using the 2-h oral glucose tolerance test (OGTT).
Results: Mean age was 20.1±8.1 years old (min.: 9.7 and max.: 48.7) and mean
weight z-score was −0.5±1.5. Of all, 56.5% were homozygous for the F508del-
CRFT mutation. All the patients were pancreatic insufﬁciency. 48.6% of patients
were colonized with Pseudomonas. The mean FEV1 was 75.4±24.1%. None recieved
antidiabetic therapy.
On OGTT, 67.5% patients were classiﬁed as NGT, 25.0% as IGT and 7.5% as CFRD.
CFRD but not IGT have insulinopenia.
Differences in weight z-score (−0.36 and −0.88); insulin 2-h (22.8 and 41.6), C peptide
2-h (2.34 and 3.54) and glycosylated haemoglobin (5.71 and 5.87) were signiﬁcant
between NGT vs. IGT together with CFRD groups respectively.
Conclusion: The prevalence of abnormal glucose tolerance in our CF population was
32.5%. IGT together with CFRD correlated with nutritional status while only CFRD
correlated with age and was associated with insulinopenia. The four-year period study
will provide information about natural evolution of GT and its predictive associated
factors.
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Objectives: Autonomic dysregulation of the nervous system is known to exist in
Cystic Fibrosis for reasons that are unclear. Hyperglycaemia has an added impact
on the development of autonomic neuropathy (AN). We examined the prevalence
of AN in 49 adult CF patients attending the All Wales Adult CF Centre.
Methods: We investigated autonomic abnormalities by undertaking Ewing’s test.
Data of the baseline clinical characteristics of patients was studied.
Results: Of the 49 patients studied (31 male) 27 patients had Cystic Fibrosis Related
Diabetes (CFRD), 8 had CF-impaired glucose tolerance (CFIGT) and 14 had CF
with normal glucose tolerance (CFNGT). The mean FEV1 percentage predicted
was 63% in CFRD, 44% in CFIGT and 54% in CFNGT groups. Evidence of
autonomic neuropathy was prevalent in all 3 groups of patients regardless of their
glycaemic status. Deﬁnite parasympathetic dysfunction was present in 71% and
29% of the CFRD and CFIGT groups respectively. 31% of patients with signs of
early autonomic dysfunction were in the CFNGT group. A positive correlation was
noted between age and abnormalities detected by Valsalva manoeuvre and deep
breathing, p = 0.001 and p = 0.000 respectively.
Conclusion: Our data suggests that other factors such as inﬂammation, more
prominent with increasing age, rather than glycaemic status exerts a greater
inﬂuence on the development of AN in CF. It is possible that patients classed
as having NGT in CF may have longstanding dysglycaemia which has not been
uncovered by the conventional method of testing in CF and therefore contributing
to the development of early AN.
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Objectives: Bone disease is now well described in cystic ﬁbrosis adult patients.
CF bone disease is multifactorial but many studies suggested the crucial role of
inﬂammation and chronic pulmonary infection. The objectives of this study were
to assess the prevalence of osteoporosis in a current adult CF population and to
examine its relationship with infections and inﬂammation.
Methods: Patients were recruited in the adult CF Lyon centre and assessed in
clinically stable period, later during an exacerbation, and ﬁnally 14 days after the
end of antibiotic therapy. At each time points, we performed a clinical evaluation,
lung function tests and biochemical tests: markers of inﬂammation (CRP, IL-6,
TNFa), serum markers of bone turnover (serum CTX), and serum RANK-L and
OPG. Absorptiometry and dorso-lumbar radiographs were also performed. We
enrolled 56 patients (29 men, mean age of 26). Bone Mineral Density (BMD)
values indicated osteopenia in 41% and osteoporosis in 14% of patients. We
found in 2 patients 1 or 2 vertebral fractures on radiographs without any history
of previous fracture. After antibiotic treatment, serum RANK-L and OPG were
increased (+24%, p = 0.08 and +13%, p = 0.04 respectively), with a stable ratio.
This increase was delayed in comparison to the increase of inﬂammation markers.
Serum CTX were stable during pulmonary exacerbation. No signiﬁcant correlation
was found between serum inﬂammation markers, CTX and RANK-L.
Conclusion: In this study, bone disease seemed to be less severe than previously
described. We found a mild increase of serum RANK-L levels, delayed compared
with the pulmonary exacerbation, and independent from the bone resorption level.
